PL2812328T3 - Modulatory kinaz Aurora i FLT3 - Google Patents

Modulatory kinaz Aurora i FLT3

Info

Publication number
PL2812328T3
PL2812328T3 PL13702642T PL13702642T PL2812328T3 PL 2812328 T3 PL2812328 T3 PL 2812328T3 PL 13702642 T PL13702642 T PL 13702642T PL 13702642 T PL13702642 T PL 13702642T PL 2812328 T3 PL2812328 T3 PL 2812328T3
Authority
PL
Poland
Prior art keywords
aurora
flt3 kinases
modulators
kinases modulators
flt3
Prior art date
Application number
PL13702642T
Other languages
English (en)
Polish (pl)
Inventor
John Charles Reader
Original Assignee
Sareum Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sareum Ltd filed Critical Sareum Ltd
Publication of PL2812328T3 publication Critical patent/PL2812328T3/pl

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL13702642T 2012-02-06 2013-02-04 Modulatory kinaz Aurora i FLT3 PL2812328T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1202027.7A GB201202027D0 (en) 2012-02-06 2012-02-06 Pharmaceutical compounds
EP13702642.3A EP2812328B1 (en) 2012-02-06 2013-02-04 Aurora and flt3 kinases modulators
PCT/EP2013/052182 WO2013117522A1 (en) 2012-02-06 2013-02-04 Aurora and flt3 kinases modulators

Publications (1)

Publication Number Publication Date
PL2812328T3 true PL2812328T3 (pl) 2016-04-29

Family

ID=45896692

Family Applications (1)

Application Number Title Priority Date Filing Date
PL13702642T PL2812328T3 (pl) 2012-02-06 2013-02-04 Modulatory kinaz Aurora i FLT3

Country Status (18)

Country Link
US (1) US9133180B2 (enExample)
EP (1) EP2812328B1 (enExample)
JP (1) JP6034880B2 (enExample)
KR (1) KR102052780B1 (enExample)
CN (1) CN104169277B (enExample)
AU (1) AU2013218167B2 (enExample)
BR (1) BR112014019254B1 (enExample)
CA (1) CA2863759C (enExample)
DK (1) DK2812328T3 (enExample)
ES (1) ES2560260T3 (enExample)
GB (1) GB201202027D0 (enExample)
IL (1) IL233988A (enExample)
MX (1) MX338481B (enExample)
PL (1) PL2812328T3 (enExample)
PT (1) PT2812328E (enExample)
RU (1) RU2643809C2 (enExample)
SG (1) SG11201404277WA (enExample)
WO (1) WO2013117522A1 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2522968B2 (ja) 1987-10-23 1996-08-07 尾池工業株式会社 印刷回路転写箔およびその製造法
JP7365332B2 (ja) * 2017-08-07 2023-10-19 ジョイント・ストック・カンパニー “バイオキャド” Cdk8/19阻害薬としての新規ヘテロ環式化合物
GB201816369D0 (en) 2018-10-08 2018-11-28 Sareum Ltd Pharmaceutical compounds

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE794096A (fr) 1972-08-07 1973-05-16 Lepetit Spa Oxazoles 2,4,5-trisubstitues et leur preparation
US4666828A (en) 1984-08-15 1987-05-19 The General Hospital Corporation Test for Huntington's disease
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4801531A (en) 1985-04-17 1989-01-31 Biotechnology Research Partners, Ltd. Apo AI/CIII genomic polymorphisms predictive of atherosclerosis
US5272057A (en) 1988-10-14 1993-12-21 Georgetown University Method of detecting a predisposition to cancer by the use of restriction fragment length polymorphism of the gene for human poly (ADP-ribose) polymerase
US5192659A (en) 1989-08-25 1993-03-09 Genetype Ag Intron sequence analysis method for detection of adjacent and remote locus alleles as haplotypes
JPH06310767A (ja) 1993-04-26 1994-11-04 Nec Corp 寒剤容器の断熱支持構造
US6218529B1 (en) 1995-07-31 2001-04-17 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate, breast and bladder cancer
WO1998004689A1 (en) 1995-07-31 1998-02-05 Urocor, Inc. Biomarkers and targets for diagnosis, prognosis and management of prostate disease
DE19653355A1 (de) 1996-12-20 1998-06-25 Dresden Arzneimittel Neue, antikonvulsiv wirkende Aminoimidazole und Verfahren zu ihrer Herstellung
GB0003154D0 (en) 2000-02-12 2000-04-05 Astrazeneca Uk Ltd Novel compounds
CN1267431C (zh) 2000-06-28 2006-08-02 阿斯特拉曾尼卡有限公司 取代的喹唑啉衍生物及其在制备作为抑制剂的药物中的用途
PL205536B1 (pl) 2000-10-30 2010-04-30 Janssen Pharmaceutica Nv Podstawiona pochodna dihydroindolu, dihydrochinoliny lub dihydroizochinoliny jako inhibitor peptydazy tripeptydowej, jej zastosowanie i sposób wytwarzania oraz kompozycja farmaceutyczna
CA2491895C (en) 2002-07-09 2011-01-18 Vertex Pharmaceuticals Incorporated Inhibitors of c-jun n-terminal kinases (jnk) and other protein kinases
AU2003902208A0 (en) * 2003-05-08 2003-05-22 Fujisawa Pharmaceutical Co., Ltd. Inhibitor of cox
ATE465731T1 (de) 2003-10-23 2010-05-15 Ab Science 2-aminoaryloxazol-verbindungen als tyrosinkinase- hemmer
BRPI0511139B8 (pt) * 2004-05-14 2021-05-25 Millennium Pharm Inc compostos que inibem quinase aurora e composição farmacêutica contendo os mesmos
GB0504753D0 (en) 2005-03-08 2005-04-13 Astrazeneca Ab Chemical compounds
WO2007043401A1 (ja) 2005-10-07 2007-04-19 Kissei Pharmaceutical Co., Ltd. 含窒素複素環化合物およびそれを含有する医薬組成物
DK200600313A (da) 2006-03-03 2006-03-13 Novo Nordisk As Treating type 2 diabetes or metabolic syndrome with an interleukin 1beta inhibitor or an interleukin 1beta synthesis or release inhibitor
DE602007009085D1 (de) 2006-05-12 2010-10-21 Ab Science Neues verfahren zur synthese von 2-aminooxazolverbindungen
US20090093452A1 (en) 2006-08-24 2009-04-09 Pfizer Inc. Pyrrole, Thiophene, Furan, Imidazole, Oxazole, and Thiazole Derivatives
JO2701B1 (en) * 2006-12-21 2013-03-03 جلاكسو جروب ليميتد Vehicles
GB0709031D0 (en) * 2007-05-10 2007-06-20 Sareum Ltd Pharmaceutical compounds
US8278335B2 (en) 2008-04-21 2012-10-02 Merck Sharp & Dohme Corp. Inhibitors of Janus kinases
GB0820819D0 (en) 2008-11-13 2008-12-24 Sareum Ltd Pharmaceutical compounds
EP2320293A1 (en) * 2009-11-05 2011-05-11 Koninklijke Philips Electronics N.V. Sleep element for improving the sleep of a person
AR079993A1 (es) * 2010-01-12 2012-03-07 Ab Science Derivados de azol, composiciones farmaceuticas y sus usos para tratar trastornos mediados por una sobreactividad de quinasas
WO2012021611A1 (en) 2010-08-11 2012-02-16 Millennium Pharmaceuticals, Inc. Heteroaryls and uses thereof
US20130231340A1 (en) 2012-03-02 2013-09-05 Sareum Limited Pharmaceutical compounds

Also Published As

Publication number Publication date
DK2812328T3 (en) 2016-01-11
KR20140128373A (ko) 2014-11-05
RU2014131784A (ru) 2016-03-27
HK1204327A1 (en) 2015-11-13
BR112014019254B1 (pt) 2020-03-10
CA2863759A1 (en) 2013-08-15
AU2013218167B2 (en) 2017-04-06
KR102052780B1 (ko) 2019-12-05
EP2812328B1 (en) 2015-11-18
SG11201404277WA (en) 2014-08-28
CN104169277B (zh) 2016-10-12
GB201202027D0 (en) 2012-03-21
RU2643809C2 (ru) 2018-02-06
CA2863759C (en) 2020-04-14
EP2812328A1 (en) 2014-12-17
BR112014019254A2 (enExample) 2017-06-20
US20150018367A1 (en) 2015-01-15
MX2014009323A (es) 2015-04-08
US9133180B2 (en) 2015-09-15
JP6034880B2 (ja) 2016-11-30
IL233988A (en) 2017-06-29
BR112014019254A8 (pt) 2017-07-11
CN104169277A (zh) 2014-11-26
ES2560260T3 (es) 2016-02-18
MX338481B (es) 2016-04-19
JP2015511228A (ja) 2015-04-16
WO2013117522A1 (en) 2013-08-15
AU2013218167A1 (en) 2014-08-14
PT2812328E (pt) 2016-03-01

Similar Documents

Publication Publication Date Title
IL262110A (en) dll3 modulators and methods to use
IL235362A0 (en) Modulators of the complement system and their use
IL245733A0 (en) aplnr modulators and their uses
PL3321268T3 (pl) Bicykliczne pochodne heteroarylowe jako modulatory mnk1 oraz mnk2 i ich zastosowania
EP2844247A4 (en) ROR MODULATORS AND ITS USES
EP2854944A4 (en) LIGHT THERAPY DEVICES AND METHOD
PL2712601T3 (pl) Sposoby i urządzenia strumieniowe
IL235826A0 (en) Diazaspirocycloalkane and azaspirocycloalkane
EP2934342A4 (en) DEVICES AND METHODS OF DISCECTOMY
AU2013203459A1 (en) DLL3 modulators and methods of use
EP2863973A4 (en) POWDER DISPERSION DEVICES AND METHOD
EP2828258A4 (en) NOVEL PYRIDOPYRIMIDINE DERIVATIVES AND THEIR USE
IL240929A0 (en) 7- Converted azabicycles and their use as orexin receptor modulators
EP2844259A4 (en) MMR MODULATORS AND USES THEREOF
IL237926A0 (en) Combinations and their uses
EP2844260A4 (en) ROR MODULATORS AND ITS USES
ZA201405392B (en) Substituted phenylimidazopyrazoles and use thereof
SG11201504482VA (en) Beta-hexosyl-transferases and uses thereof
SG11201404277WA (en) Aurora and flt3 kinases modulators
GB201222541D0 (en) Kiddibidet and pottibidet
IL218974A0 (en) Conaction bitwen coutch and playels
GB201202021D0 (en) Co-sleeper and breastfeeder
GB201209483D0 (en) Spirit level and attachment